TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03409016

Intervention type: OTHER
Intervention: Blood Testing
Description: Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.

Intervention type: OTHER
Intervention: Blood Testing
Description: Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
Study: NCT01561014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo F18 PET and CT scan
Study: NCT01440959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
Study: NCT03814811

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Osteocalcin-positive (cOC) cells
Description: Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Osteocalcin-positive (cOC) cells
Description: Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Osteocalcin-positive (cOC) cells
Description: Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Osteocalcin-positive (cOC) cells
Description: Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
Study: NCT02476617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: ombitasvir/ABT-450/ritonavir tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: dasabuvir tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: ribavirin tablets
Study: NCT02689440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04146597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
Study: NCT01876836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: i-gel placed after induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-LMA
Description: placed after induction
Study: NCT01495949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate
Description: During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiopentone
Description: During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
Study: NCT00580619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Function Testing
Description: The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline infusions
Description: The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA trimethaphan
Description: Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyldopa
Description: Aldomet oral twice a day for 12 weeks
Study: NCT00900653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynoflor E (low dose estriol with lactobacillus)
Description: The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
Study: NCT01630148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin
Description: Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
Study: NCT00325897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrolide Antibiotic (Azithromycin)
Description: Azithromycin (daily capsule, 250 mg for 12 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken on a daily basis
Study: NCT04410523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.
Study: NCT04150614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Transdermal Patch
Description: Antiemetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Description: Antiemetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Description: Antiemetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron
Study: NCT04476862

Intervention type: DRUG
Intervention: Cerliponase Alfa
Description: Commercially available product provided to patient by participating clinic site.

Intervention type: DEVICE
Intervention: Administration Kit
Description: Commercially available administration kit provided to the patient by participating clinic site.
Study: NCT01727284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-guided cryoablation
Study: NCT04008745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and home-based physical therapy by foot-related exercises
Description: The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
Study: NCT04097678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retained Surgical Sponge
Description: A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
Study: NCT03350529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided transurethral HIFU ablation of prostatic tissue
Description: The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided transurethral HIFU ablation of prostatic tissue
Description: The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided transurethral HIFU ablation of prostatic tissue
Description: The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided transurethral HIFU ablation of prostatic tissue
Description: The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
Study: NCT02731638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrastromal voriconazole
Description: Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natamycin
Description: Subjects will receive topical 5% natamycin drops hourly for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natamycin
Description: Subjects will receive topical 5% natamycin drops hourly for 3 days.
Study: NCT04091048

Intervention type: DEVICE
Intervention: Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Description: Aortic valve replacement
Study: NCT02340026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Supported Mobility
Description: Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child
Study: NCT01436149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate )
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Study: NCT01058980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional ablation until elimination of dormant conduction
Description: Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No additional ablation
Description: Presence of dormant PV conduction, no additional ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Registry group
Description: Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
Study: NCT02380573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FD&C Blue # 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FD&C Blue # 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FD&C Blue # 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FD&C Blue # 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenazopyridine hydrochloride
Study: NCT00996476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
Study: NCT04080661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Description: The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
Study: NCT03286036

Intervention type: OTHER
Intervention: biomarkers
Description: This is an observational study, there is no intervention
Study: NCT04216524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT06281587

Intervention type: PROCEDURE
Intervention: penetrating keratoplasty
Description: replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.

Intervention type: PROCEDURE
Intervention: penetrating keratoplasty
Description: replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.
Study: NCT00996476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a
Description: One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a
Description: One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a
Description: One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a
Description: One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.